Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Zevra Therapeutics Inc (Zevra) is a is a commercial-stage company focused on developing and commercializing therapies for patients with rare diseases. The company's products include Miplyffa (arimoclomol), a therapy for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients aged and older, and Olpruva (sodium phenylbutyrate), an oral suspension therapy for certain urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). Zevra Therapeutics is headquartered in Celebration, Florida, the US.
Headquarters
United States of America
Address
Suite 103, 1180 Celebration Boulevard, Florida, 34747
Website
zevra.com
Telephone
1 888 9581253
No of Employees
61
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZVRA (NASD)
Revenue (2024)
$106.5M
350.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
178.9%
(2024 vs 2023)
Market Cap*
$609.9M
Net Profit Margin (2024)
XYZ
117.5%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Miplyffa (arimoclomol): Niemann-Pick Disease Type C (NPC)Arimoclomol Capsules: Niemann-Olpruva (sodium phenylbutyrate): Certain Urea Cycle Disorders (UCDs) | AZSTARYS |
| MIPLYFFA | |
| OLPRUVA |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In November, the company announced the acquisition of Acer Therapeutics. |
| 2023 | Corporate Changes/Expansions | In February, the company changed its name to Zevra Therapeutics Inc. |
| 2023 | Contracts/Agreements | In January, the company entered into an agreement with Hypersomnia Foundation to promote research and advocacy for sleep disorder. |
Competitor Comparison
| Key Parameters | Zevra Therapeutics Inc | Collegium Pharmaceutical Inc | Acura Pharmaceuticals Inc | SELLAS Life Sciences Group Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Celebration | Stoughton | Palatine | New York City |
| State/Province | Florida | Massachusetts | Illinois | New York |
| No. of Employees | 61 | 423 | - | 13 |
| Entity Type | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Neil F. McFarlane | President; Director; Chief Executive Officer | Executive Board | 2023 | 53 |
| Justin Renz | Chief Financial Officer | Senior Management | 2026 | 54 |
| Rahsaan W. Thompson | Secretary; Compliance Officer; Chief Legal Officer | Senior Management | - | 55 |
| Alison Peters | Chief People Officer | Senior Management | - | - |
| Adrian Quartel, M.D | Chief Medical Officer | Senior Management | - | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer